ArticleJournal of clinical practice and research2025
Oleuropein Administration Alleviates Nerve Damage Induced by Sciatic Nerve Constriction Injury in Rats.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Oleuropein has previously been reported to provide neuroprotection in ischemia/reperfusion injury and to alleviate allodynia in neuropathic pain models. This study aims to assess the therapeutic potential of oleuropein, a polyphenolic compound found in olive trees, on sciatic nerve damage induced by chronic constriction injury (CCI) in male rats by comparing its efficacy with gabapentin, a widely used antiepileptic drug for the treatment of neuropathic pain. Materials and Methods: Adult male Wistar rats were randomly allocated into control, neuropathic pain (NP), NP treated with 15 mg/kg oleuropein, and NP treated with 100 mg/kg gabapentin groups. The neuropathic pain model was induced by CCI via ligation of the sciatic nerve at four different locations, each separated by an interval of 1 mm. Treatments were administered via oral gavage for 14 days. Nociceptive behavior in response to thermal stimuli and the sciatic functional index (SFI) were assessed weekly. Nerve conduction velocity, sciatic nerve histology, and the level of thiobarbituric acid reactive substances were evaluated at the end of treatment. Results: Sciatic CCI led to a reduction in nerve conduction and function, increased oxidative stress, and altered neuronal integrity, accompanied by decreased myelin sheath thickness and myelinated fiber diameter. Oleuropein administration significantly increased nerve conduction velocity, improved SFI values over time, significantly reduced oxidative stress, and enhanced neuronal integrity and myelination, surpassing the effects of gabapentin administration. Conclusion: These findings highlight the therapeutic potential of oleuropein in nerve constriction injury and nerve damage, warranting further investigation into its use for nerve injury treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.